Welcome to the Maggirwar Lab
This Is What We Do
Thanks to the success of combination antiretroviral therapy (cART), people are now living much longer with HIV infection. However, despite excellent control of viral replication with cART, HIV-infected patients are suffering from inflammatory secondary complications of HIV infection at a much higher rate than their aging, uninfected counterparts. These inflammatory secondary disorders include, most notably, cardiovascular disease (CVD) and neurocognitive impairment. Our lab is interested in determining the mechanisms by which both host factors and viral components are contributing to these disorders. Specifically, we are focusing on the cellular antiviral protein, tetherin, and the role of tetherin in HIV-induced microparticle production in monocytes. Microparticles are important proinflammatory mediators during the development of CVD. We are also interested in the dysregulation of signaling events in CNS cell types, such as astrocytes, microglia, pericytes, and brain endothelial cells, all of which contribute to HIV-induced neurocognitive impairment.
- Humoral Dysregulation Associated with Increased Systemic Inflammation among Injection Heroin Users.PLoS One. 11, e0158641. (2016 Jan 01).
- Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis.PLoS One. 11, e0157115. (2016 Jan 01).
- Smoothened Agonist Reduces Human Immunodeficiency Virus Type-1-Induced Blood-Brain Barrier Breakdown in Humanized Mice.Sci Rep. 6, 26876. (2016 Jan 01).